Market research
SP4P.F Achieve Life Sciences, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 695M
- P/E ratio
- Not available
- Analyst target
- 36.71
- Dividend yield
- Not available
- Beta
- 2.23
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0044685008
- Market cap
- 695M
- P/E ratio
- Not available
- Analyst target
- 36.71
- Dividend yield
- Not available
- Beta
- 2.23
About
About Achieve Life Sciences, Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SP4P.F discussion.
5 years, 5 months ago
Achieve Life Sciences, Inc is currently in a long term downtrend where the price is trading 18.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Achieve Life Sciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 47.9% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 27.4% to $-2M since the same quarter in the previous year.
Based on the above factors, Achieve Life Sciences, Inc gets an overall score of 2/5.